Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125520632 | 12552063 | 2 | F | 20160722 | 20160713 | 20160802 | EXP | FR-GLENMARK PHARMACEUTICALS INC, USA.-2016GMK023595 | GLENMARK | LELIEVRE B, PASQUIER C, DROUILLARD I, THILL C, FEREC S, LE ROUX G, BRUNEAU C, BRETAUDEAU DEGUIGNE M, TURCANT A, BOELS D.. SEVERE NAPROXEN INTOXICATION RESULTING IN COAGULOPATHY. [FRENCH]. TOXICOLOGIE ANALYTIQUE ET CLINIQUE.. 2016;28(1):38-42 | 58.00 | YR | F | Y | 0.00000 | 20160802 | OT | FR | FR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125520632 | 12552063 | 1 | PS | NAPROXEN. | NAPROXEN | 1 | Oral | 26 G, UNK | U | 78250 | 26 | G | |||||||
| 125520632 | 12552063 | 2 | SS | NAPROXEN. | NAPROXEN | 1 | UNK | U | 78250 | ||||||||||
| 125520632 | 12552063 | 3 | SS | CITALOPRAM HYDROBROMIDE. | CITALOPRAM HYDROBROMIDE | 1 | Oral | 10 MG, UNK | U | 0 | 10 | MG | |||||||
| 125520632 | 12552063 | 4 | SS | ACEBUTOLOL | ACEBUTOLOL | 1 | Oral | 200 MG, UNK | U | 0 | 200 | MG | |||||||
| 125520632 | 12552063 | 5 | SS | OXAZEPAM. | OXAZEPAM | 1 | Oral | 50 MG, UNK | U | 0 | 50 | MG | |||||||
| 125520632 | 12552063 | 6 | SS | ZOPICLONE | ZOPICLONE | 1 | Oral | 7.5 MG, UNK | U | 0 | 7.5 | MG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125520632 | 12552063 | 1 | Product used for unknown indication |
| 125520632 | 12552063 | 3 | Product used for unknown indication |
| 125520632 | 12552063 | 4 | Product used for unknown indication |
| 125520632 | 12552063 | 5 | Product used for unknown indication |
| 125520632 | 12552063 | 6 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125520632 | 12552063 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125520632 | 12552063 | Bradycardia | |
| 125520632 | 12552063 | Cardiac disorder | |
| 125520632 | 12552063 | Coagulopathy | |
| 125520632 | 12552063 | Electrocardiogram QT prolonged | |
| 125520632 | 12552063 | Haemodynamic instability | |
| 125520632 | 12552063 | Haemostasis | |
| 125520632 | 12552063 | Hypocoagulable state | |
| 125520632 | 12552063 | Hypotension | |
| 125520632 | 12552063 | Intentional overdose | |
| 125520632 | 12552063 | Lactic acidosis | |
| 125520632 | 12552063 | Metabolic acidosis | |
| 125520632 | 12552063 | Pneumonia aspiration | |
| 125520632 | 12552063 | Thrombocytopenia | |
| 125520632 | 12552063 | Toxicity to various agents |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |